Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
An integrated surveillance system for infectious disease in rural China: generating evidence for early detection of disease epidemics in resource-poor settings. (ISSC)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Collaborative project
Countries involved: Sweden,China,Germany,Sweden
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-03-01
End date: 2014-12-31
Duration (months): 58.0
Total project cost (EUR): 3898390.8
EU funding (EUR): 2967837.0
Participants: 5
Project status: CLOSED

Background A crucial goal of infectious disease surveillance is the early detection of epidemics, which is essential for disease control. In China, the current surveillance system is based on confirmed case reports and only covers notifiable diseases. In rural China, it is not practical for health units to perform laboratory tests to confirm disease and people are more likely to get 'old' and emerging infectious diseases due to poor living conditions and closer contacts with wild animals and poultry. Syndromic surveillance which collects non-specific syndromes before diagnosis has great advantages in promoting the early detection of epidemics and reducing the necessities of disease confirmation. It will be especially effective for surveillance in resource poor settings. Objectives The objective is to improve the early detection of epidemics in rural China by integrating syndromic surveillance with case report surveillance system. This involves three main phases: (1) the development of an integrated surveillance system; (2) the implementation of this system; (3) the evaluation of this system. This project will contribute to knowledge, experience and evidence with regard to the development and implementation of an integrated surveillance system for the early warning of epidemics in similar settings. Methods This is an intervention study. The intervention tool will be an integrated surveillance system, combining syndromic surveillance with the existing case report surveillance in four selected counties in China. In order to evaluate the early warning capability of the new added syndromic surveillance, the timelines and validity of the alert signals triggered from syndromic surveillance will be compared against those from corresponding case report surveillance (as a reference) for the same region and time period. The acceptability, feasibility and economic evaluation of the whole integrated surveillance system will be conducted in a before and after study design.

Keywords: integrated surveillance system,syndromic surveillance,early warning,infectious disease,outbreak detection
Total Airport Security System (TASS)

Framework: FP7 — Cooperation
Programme: Security
Destination: Increasing the Security of infrastructures and utilities
Action type: Collaborative project
Countries involved: Spain,Italy,Greece,Portugal,France,Ireland,Israel,France,France,United Kingdom,Sweden,United Kingdom,Sweden
Call:  (FP7-SEC-2009-1, 2009)
Start date: 2010-04-01
End date: 2014-03-31
Duration (months): 48.0
Total project cost (EUR): 14966376.75
EU funding (EUR): 8986696.15
Participants: 22
Project status: CLOSED

TASS is a multi-segment, multi-level intelligence and surveillance system, aimed at creating an entire airport security monitoring solution providing real-time accurate situational awareness to airport authorities.The TASS concept is based on integrating different types of selected real time sensors &amp; sub-systems for data collection in a variety of modes, including fixed and mobile, all suitable for operation under any environmental conditions. TASS divides the airport security into six security control segments (environmental, cargo, people, airplanes, vehicle-fleet &amp; facilities) each of them being monitored by various technologies that are fused together, creating a multisource labyrinth fusion logic enabling situational and security awareness of the airport anytime and anywhere. These fused control segments will be accessed through the TASS WEB-based portal by running a suite of applications making the airport security control centralized to all airport authorities. Information will be shared and synchronized between all of them in order to generate a comprehensive, real time, security overview for the airport C2, providing all the necessary features to assure a total “no breach” security environment. The integration will include the use of in-place technologies that will result in a cost-effective solution.The TASS consortium consists of 3 main end users representing 16 airports and 16 technological partners, which bring together European SME’s, industrial and academic partners, ranging from sensor design and electronic communications through to civil airport protection. The technologies will be tested at 3 airports including the hub airport Heathrow, an Israeli domestic airport and Athens airport, in order to cover a wide range of needs at different levels of airport protection. The main test at Heathrow airport will involve scenarios including 2 connected to the upcoming 2012 Olympic Games in London ultimately resulting in a high &amp; smooth passengers flow.

Keywords: passengers,airport,command and control centre,data fusion,web portal,sensors,detection,monitoring,security,surveillance
European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Netherlands,United Kingdom,United Kingdom,Germany,Türkiye,Spain,Netherlands,France,Belgium,Greece,Austria,Switzerland,Germany,Hong Kong,Spain,United Kingdom,Ireland,Germany,Italy,Italy,Australia,Netherlands
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-05-01
End date: 2015-04-30
Duration (months): 60.0
Total project cost (EUR): 15030922.89
EU funding (EUR): 11616855.0
Participants: 26
Project status: CLOSED

The aim of EU-GEI is to identify the interactive genetic, clinical and environmental determinants involved in the development, severity and outcome of schizophrenia (EU-GEI, Schiz. Res. 2008; 102: 21-6). In order to identify these interactive determinants, EU-GEI will employ family-based, multidisciplinary research paradigms, which allow for the efficient assessment of gene-environment interactions. In order to go beyond old findings from historical convenience cohorts with crude measures of environmental factors and clinical outcomes, the focus in EU-GEI will be on recruitment of new, family-based clinical samples with state-of-the-art assessments of environmental, clinical and genetic determinants as well as their underlying neural and behavioural mechanisms. New statistical tools will be developed to combine the latest multilevel epidemiological with the latest genome-wide genetic approaches to analysis. Translation of results to clinical practice will be facilitated by additional experimental research and risk assessment bioinformatics approaches. This will result in the identification of modifiable biological and cognitive mechanisms underlying gene-environment interactions and the construction of Risk Assessment Charts and Momentary Assessment Technology tools which can be used for (i) early prediction of transition to psychotic disorder in help-seeking individuals with an at-risk mental state and (ii) early prediction of course and outcome after illness onset. In order to reach these goals, EU-GEI has assembled a multidisciplinary team of top schizophrenia researchers who have the range of skills required to deliver a program of research that meets all the call’s requirements and who have access to / will collect a number of unique European samples. The partners in EU-GEI represent the nationally funded schizophrenia / mental health networks of the UK, Netherlands, France, Spain, Turkey and Germany as well as other partners.

Keywords: schizophrenia,genetics,environment,gene-environment interaction,prodrome,course,prediction
The role of intestinal microflora in non-alcoholic fatty liver disease (NAFLD) (FLORINASH)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: France,Spain,Italy,United Kingdom
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-01-01
End date: 2014-12-31
Duration (months): 60.0
Total project cost (EUR): 7494793.45
EU funding (EUR): 5729810.0
Participants: 6
Project status: CLOSED

As worldwide metabolic disease pandemics rise relentlessly with their concomitant clinical complications such as non alcoholic fatty liver disease, FLORINASH proposes an innovative research concept to address the role of intestinal microfloral activity in the pathogenesis of NAFLD. Firstly, to discover novel metabolic markers for the differential diagnosis and prediction of patient risk. Secondly, to identify HITS as targets for new therapeutic or interventional approaches. The strength of the FLORINASH proposal lies in: i) The construction a large bank of tissues and biofluids (liver biopsies, urine, faeces, plasma) from NAFLD patients that have been phenotyped for obesity and for insulin resistance by hyperinsulinemic clamping. ii) The application of coupled bioinformatic and chemometric modelling of phenotypes via advanced system level omics metrics (utilizing metabolomic, proteomic, transcriptomic, and metagenomic platforms). iii) The mechanistic refinement and validation of human markers and target-HITS in complementary animal models and innovative humanized mice. iv) To validate currently available therapeutic candidates for the target-HITS and synthesize new chemical entities to interfere with these target-HITS. v) To elucidate and widely disseminate the systemic and long range metabolic impacts of intestinal microflora modulation on molecular pathways such as ER stress, lipogenic transcription factors and inflammatory agents. Hence, in addition to fundamental scientific advances that can be tranlated to individual healthcare scenarios, the European community will benefit more widely from numerous social, economical, clinical, scientific impacts resulting from the FLORINASH project.

Keywords: inflammation,nutrition,diabetes,obesity,microflora,er stress,lps,cd14,timp3,nash nafld
Genetic and Epigenetic Networks in Cognitive Dysfunction (GENCODYS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Netherlands,Germany,France,Iran, Islamic Republic of,United Kingdom,Austria,United Kingdom,France,United Kingdom,United Kingdom,Netherlands,United Kingdom,Belgium,Pakistan
Call:  (FP7-HEALTH-2009-two-stage, 2009)
Start date: 2010-05-01
End date: 2015-04-30
Duration (months): 60.0
Total project cost (EUR): 16027532.8
EU funding (EUR): 11647068.0
Participants: 15
Project status: CLOSED

Mutations in about 400 different genes have been associated with Cognitive Disorders (CD), such as mental retardation, autism, neurodegenerative disorders, and psychiatric disorders. Whereas CD impose a major medical and socio-economical problem, there are no systematic studies that aim to provide insight into common mechanisms in CD. We propose a systems biology approach to gain insight into common mechanisms leading to cognitive impairment: (1) Identification of genes involved in cognitive disorders. Despite considerable progress in the identification of genes underlying CD, the majority of causative genes in CD remain unidentified. Therefore, our first objective is to identify new genes causative of CD by implementing high-throughput strategies. (2) Elucidation of molecular networks that are commonly disrupted in CD. Recent genetic and neurobiological research revealed evidence for a number of molecular and cellular pathways that are shared by the various genetic CDs. Prominent examples are Rho GTPase-related genes and genes that regulate chromatin structure/function (epigenetics) associated with mental retardation and autism. Our second objective is to systematically explore this concept by elucidation of molecular networks using functional genomics strategies in genetic models that are the cornerstone of neuroscience, such as mouse and fruit fly. (3) Identify genetic modifiers and small compounds that modulate the disease phenotype. Our third objective is to resolve the molecular underpinnings of the large degree of clinical variability that is typical for all types of CD, even among patients carrying identical gene mutations. Genetic modifier screens in cultured primary neurons as well as in available Drosophila models for CD will be used to reveal phenotypically relevant genetic interactions and molecular networks. Moreover, drug screens shall be conducted in fly and cellular models for CD, which will lead to pharmacological rescue of mouse models.

Keywords: cogntive dysfunction,genetics,genomics,epigenetics,drosophila,mouse,functional genomics,proteomics,transcriptomics,high throughput sequencing,microarray,learning,synapse
Clinical development of a Pfs48/45-based malaria transmission blocking vaccine (REDMAL)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Netherlands,Denmark,United Kingdom,Tanzania, United Republic of,India
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-03-01
End date: 2014-11-30
Duration (months): 57.0
Total project cost (EUR): 4579673.6
EU funding (EUR): 2999998.0
Participants: 6
Project status: CLOSED

Malaria vaccines are needed to reduce the unacceptably high burden of disease and death in particular in the lowest income countries. Malaria vaccines aim at interruption of the life cycle of the parasite Plasmodium falciparum by induced immune responses in the humans. Transmission-blocking vaccines (TBMV) specifically aim at an arrest sexual stage development preventing the generation of infectious mosquitoes. TBMVs are the most effective tools for reduction of the spread of malaria in the population. This is indispensible for sustained control, elimination and eventually eradication. Pfs48/45 is the most advanced EU-developed malaria TBMV candidate. PF10C is a subunit of Pfs48/45 that has been produced as R0-PF10C in a 20L fermentor. Immunization with 100% properly folded R0-PF10C induced transmission-blocking activity in 100% of immunized mice. Objectives: 1) Manufacture R0-PF10C at cGMP grade and 2) Prepare for clinical trials with R0-PF10C in Africa. Workplan: R0-PF10C production will be optimized and up-scaled for release of clinical grade batches for human trials. To prepare for clinical testing to Africa, preparation for Phase II will be initiated. A Phase II trial of a malaria TB vaccine will require a specific design. Important transmission parameters will be collected and introduced in a mathematical model to study the possible impact on transmission in the selected study area. Milestones: 1) Batch release R0-PF10C for use in clinical trial; 2) Preparation of field site for phase IIb clinical trial with R0-PF10C vaccine

Keywords: malaria,vaccine,transmission blocking,clinical trials,epidemiology,pfs48/45,adjuvants,cgmp
EUropean Reanalysis and Observations for Monitoring (EURO4M)

Framework: FP7 — Cooperation
Programme: Space
Destination: Space-based applications at the service of the European Society
Action type: Collaborative project
Countries involved: Netherlands,United Kingdom,Spain,Romania,Switzerland,Germany,Sweden,United Kingdom,France
Call:  (FP7-SPACE-2009-1, 2009)
Start date: 2010-04-01
End date: 2014-03-31
Duration (months): 48.0
Total project cost (EUR): 6629960.0
EU funding (EUR): 3989200.0
Participants: 9
Project status: CLOSED

EURO4M will develop the capacity for, and deliver the best possible and most complete (gridded) climate change time series and monitoring services covering all of Europe. These will describe the evolution of the Earth system components by seamlessly combining two different but complementary approaches: regional observation datasets of Essential Climate Variables (ECVs) on the one hand and model based regional reanalysis on the other. The project will extend, in a cost effective manner, European capacity to systematically monitor climate variability and change (including extremes) on a range of space and time scales. EURO4M will reach out with innovative and integrated data products and climate change services to policy-makers, researchers, planners and citizens at European, national and local levels. This will directly address the needs of, for instance, the European Environment Agency for their environmental assessment reports - and even provide online reporting during emerging extreme events. As the primary source of timely, targeted and reliable information about the state of the climate in Europe, the suggested collaborative project is an important building block for GMES. The project will integrate and extend core services activities on ECVs, specifically developing the capacity required for state-of-the-art user-oriented products for monitoring of climate change. EURO4M has the potential to evolve into a future GMES service on climate change monitoring that is fully complimentary and supporting the existing operational services.

Keywords: reanalysis monitoring observations
Construction kit for tailor-made vascularized boneimplants (VASCUBONE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Germany,Sweden,Sweden,Germany,Norway,Germany,Austria,Austria,Germany,Germany,Germany,Germany
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-01-01
End date: 2015-03-31
Duration (months): 63.0
Total project cost (EUR): 15569959.44
EU funding (EUR): 11966071.0
Participants: 18
Project status: CLOSED

The goal of VascuBone is to develop a “tool box” for bone regeneration, which on one hand fulfils basic requirements and on the other hand is freely combinable with what is needed in the respective patient’s situation. The tool box will include a variation of biocompatible biomaterials and cell types, FDA approved growth factors, material modification technologies, simulation and analytical tools like molecular imaging based in vivo diagnostics which can be combined for the specific medical need. This tool box will be used to develop translational approaches for regenerative therapies of three different types of bone defects. The chosen bone diseases differ in their requirements, to ensure a successful implementation and translation. Additionally this implementation strategy is characterized by high complexity to remove bottlenecks and limitations of bone regeneration identified in the clinical setting. Therefore definite quality criteria have to be evaluated concerning an optimal stem cell source/subpopulation as well as GF concentrations and their bioactivity in vivo. Furthermore quantitative evaluation will focus on the definition of differences between stem cell populations responsible for bone regeneration in young and old people, as a prerequisite for the development of regenerative therapies for the ageing European society. Considering a successful and prompt approval of the biomaterial, for each clinical application a minimum of modification steps in daily routine must be identified. The road map of the project and clinic trials contains pre-determined milestones, to ensure efficacy, safety, and immunological acceptance of the implant. The efficacy is quantified by high innovative MRI and PET/CT technology which is able to demonstrate the regenerative effect of biomaterials and cells in vivo. Based on the clinical data the proposal as “Advanced Therapeutical Medicinal Product” will be submitted to the European Medicines Agency at the end of the project.
Consortium on Health and Ageing: Network of Cohorts in Europe and the United States (CHANCES)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: Greece,Sweden,Netherlands,Netherlands,Germany,Denmark,Netherlands,Germany,United Kingdom,Finland,France,United States,United Kingdom,Norway,Germany,Germany
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-02-01
End date: 2015-01-31
Duration (months): 60.0
Total project cost (EUR): 15410903.21
EU funding (EUR): 11932398.0
Participants: 17
Project status: CLOSED

CHANCES aims at combining and integrating on-going cohort studies in order to produce evidence on ageing-related health characteristics and determinants in Europe, and their socio-economic implications. 15 cohorts participate, covering populations from 18 EU Member States, 4 associate countries, and 3 additional countries. The combination of these different studies would lead to an integrated approach to the study of health in the elderly. CHANCES will address 5 main types of health related characteristics: (i) incidence of chronic conditions, disabilities and mortality; (ii) prevalence of chronic conditions and disabilities; (iii) health-related determinants of chronic conditions and disabilities; (iv) ageing-related characteristics as determinants of chronic condition, disabilities and mortality; and (v) social and economic implications of chronic conditions, disabilities and mortality in the elderly. Analyses will be conducted in subjects aged 50-59, 60-69 and 70+ years. Health-related determinants comprise (i) socio-economic factors (e.g., education, income), (ii) environmental factors (e.g., occupational exposures), (iii) lifestyle factors (e.g., tobacco smoking, alcohol drinking), and (iv) nutritional factors (e.g., BMI, dietary patterns), in addition to biomakers and genetic factors. 4 major groups of chronic conditions and disabilities will be studied: (i) cancer; (ii) diabetes and cardiovascular diseases; (iii) fractures and osteoporosis; (iv) cognitive function and Alzheimer disease. Information on other conditions and disabilities (e.g., eye diseases, chronic respiratory conditions) will be also collected if available. Mortality will be assessed in terms of age-specific rates a well as DALYs. A health module will be developed, to be applied to other population surveys. Additionally, the study will generate a unique resource for additional studies on health and its determinants in the elderly. Provisions will be made to allow for this work to be extended.